Incannex healthcare inc. provides clinical program update on ihl-42x, an oral once-daily treatment for obstructive sleep apnea (osa)

Patient dosing completed in phase 2 portion of phase 2/3 reposa study evaluating ihl-42x oral treatment for osa. end-of-study follow-up assessments on track for completion by may 17, 2025.

OSA Ratings Summary

OSA Quant Ranking